# Lixte Biotechnology Holdings Inc. (LIXT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $332M  
**Price:** $6.93 (+0.65%)

> Lixte Biotechnology Holdings Inc. is a biotechnology company specializing in the research and development of treatments aimed at addressing various forms of cancer and other serious diseases. The primary function of Lixte is to innovate in the field of drug development by focusing on novel compounds that can serve as potential therapeutics. Notably, the company concentrates on identifying and developing small molecule inhibitors that target specific pharmacological pathways involved in cancer progression and other diseases. Lixte operates primarily within the biotechnology and pharmaceutical sectors, holding significance for its contribution to potentially groundbreaking cancer therapies. By focusing on a niche market in oncology and the broader healthcare industry, Lixte Biotechnology Holdings Inc. plays a critical role in advancing scientific research and offering new hope in the fight against complex diseases. Its activities exemplify the intersection of cutting-edge science and the quest for effective clinical solutions in a highly dynamic and innovative sector.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2015 | $200,000 | $175,000 | -$3M | -$3M | — |
| 2013 | — | — | -$1M | -$1M | — |
| 2012 | — | — | -$2M | -$4M | — |
| 2011 | — | — | -$2M | -$2M | — |
| 2010 | — | — | -$881,684 | -$880,250 | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2015 | $597,975 | $285,642 | $312,333 | $25,281 | — |
| 2013 | $558,040 | $321,774 | $236,266 | $475,019 | — |
| 2012 | $2M | $261,152 | $1M | $2M | — |
| 2011 | $429,767 | $350,746 | $79,021 | — | — |
| 2010 | $2M | $195,062 | $2M | — | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$3M | — | — |
| 2024 | -$3M | — | — |
| 2023 | -$4M | — | — |
| 2022 | -$5M | — | — |
| 2021 | -$4M | — | — |
| 2020 | -$2M | — | — |
| 2019 | $2M | — | — |
| 2018 | -$2M | — | — |
| 2017 | -$1M | — | — |
| 2016 | -$2M | — | — |
| 2015 | -$2M | — | — |
| 2014 | -$2M | — | — |
| 2013 | -$1M | — | — |
| 2012 | -$1M | — | — |
| 2011 | -$1M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/LIXT)